{"ticker": {"uuid": "7a944193-f62c-4f62-bbcb-8bdf35b6da15", "symbol": "TARS", "name": "Tarsus Pharmaceuticals\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPS1lQZjZ1ZF9tNUZrR3gtYjZ3OGtFbE10R09neUU4Q0p2LWx5OFhLQW9VWGc0SEllRUluTDlxX3c4UU1WMmc1M3V6OGdHTXJKeWNoS3B5RkFCSi05V2VhR0o3bE1QalJOU3Q2VWdNdlE3TUtWNERudkN2YnIyck1JeGZ3NUxrRTlaRGlscTVJMUJEekhZUjBsY1gwT29tYXlrTWVidWc4TThxZHl1Tjh3UURQMG83aVc5Vk5DLTV2WE5EeXdSR2hFTFZSbHpxaEItdU9sbGp6cUYycDVmOVhmbDRWT3FpZw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-17T20:01:42+00:00", "published_display": "17 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/tarsus-pharmaceuticals-tars-replaces-commercial-021119140.html", "source_name": "Simply Wall St.", "published_at": "2026-07-16T02:11:19+00:00", "published_display": "16 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)", "summary": "Analysts have provided new ratings for UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS) in the Healthcare sector. TD Cowen maintained a Hold rating on UnitedHealth with a $430.00 price target, while Mizuho Securities maintained a Buy rating on Tarsus Pharmaceuticals with a $1", "url": "https://www.theglobeandmail.com/investing/markets/stocks/UNH/pressreleases/3290444/analysts-offer-insights-on-healthcare-companies-unitedhealth-unh-and-tarsus-pharmaceuticals-tars/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T11:40:13", "published_display": "15 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Announces Executive Leadership Transition", "summary": "Tarsus Pharmaceuticals has announced a leadership transition where Neera Clase, previously senior vice president of market access, will serve as interim chief commercial officer. This follows the departure of Aziz Mottiwala, who is leaving to become CEO of a public medical device", "url": "https://www.visionmonday.com/eyecare/article/tarsus-pharmaceuticals-announces-executive-leadership-transition/", "source_name": "VisionMonday.com", "published_at": "2026-07-15T04:19:20", "published_display": "15 Jul 2026 04:19", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Chief Commercial Officer Departs", "summary": "Tarsus Pharmaceuticals Inc. announced that its Chief Commercial Officer, Aziz Mottiwala, is departing to become the CEO of an unnamed publicly traded medical device company. Neera Clase, previously SVP of market access, will serve as interim CCO. Following the announcement, share", "url": "https://www.ocbj.com/healthcare/tarsus-chief-commercial-officer-departs/", "source_name": "Orange County Business Journal", "published_at": "2026-07-14T17:11:12", "published_display": "14 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals acquires iRenix for $75 million upfront By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOTlI1eGprT3JJV3ZVc19LMWx1ODR0a3FkajVWMll0ZkZQSl9HMmdPa3YtQ1BmZXNrLUZGSlpwTktSVzZWTkIzUGNreVFKMk5yVTgxWi1wRDdJXy1lRmhVbm13RzZXdy1xMFJVS2FET3JFbHYyaFlnM1dmeUJGNmFqM1pQa0lBSEdZMHRncF9aelUzYkZkc0E4a1UxTzJVUWo2bm9BUURQQlJ5eEdMV29NY0oyanY4Q3JpN2RaNUZhNA?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T15:38:03+00:00", "published_display": "14 Jul 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Tarsus commercial executive departs as eye drug XDEMVY gains traction", "summary": "Tarsus Pharmaceuticals announced that Chief Commercial Officer Aziz Mottiwala has left the company to become CEO of a public medical device company. Neera Clase, formerly Senior Vice President of Market Access, has been appointed Interim Chief Commercial Officer. This leadership ", "url": "https://www.stocktitan.net/news/TARS/tarsus-pharmaceuticals-announces-executive-leadership-transition-as-5px5sfcajtke.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:10:21", "published_display": "14 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth", "summary": "Tarsus Pharmaceuticals announced a significant executive leadership transition as the company prepares for its next phase of growth, following the anticipated FDA approval of XDEMVY and its commercial launch. Wendy White is departing from her role as Chief Commercial Officer to p", "url": "https://www.moomoo.com/news/post/72878272/press-release-tarsus-pharmaceuticals-announces-executive-leadership-transition-as-company?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T11:40:13", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/tarsus-pharmaceuticals-appoints-neera-clase-204124445.html", "source_name": "MT Newswires", "published_at": "2026-07-13T20:41:24+00:00", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event", "summary": "Tarsus Pharmaceuticals, Inc. (TARS) announced a material event via an 8-K filing, reporting a leadership change within its commercial organization. Aziz Mottiwala, the Chief Commercial Officer, will depart the company on July 15, 2026, to become the Chief Executive Officer of a p", "url": "https://www.stocktitan.net/sec-filings/TARS/8-k-tarsus-pharmaceuticals-inc-reports-material-event-6d9d590d6719.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:50", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth", "summary": "Tarsus Pharmaceuticals announced an executive leadership transition as Chief Commercial Officer Aziz Mottiwala departs to become CEO of a public medical device company. Neera Clase, previously Senior Vice President of Market Access, has been appointed Interim Chief Commercial Off", "url": "https://ca.finance.yahoo.com/news/tarsus-pharmaceuticals-announces-executive-leadership-200500521.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-13T19:41:50", "published_display": "13 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical, integrating IRX-101, a late-stage ocular surface antiseptic, into its pipeline to expand into the retina market. IRX-101 aims to improve the experience for patients undergoing intravitreal injections by offering a better alterna", "url": "https://www.tradingview.com/news/marketbeat:de5852955094b:0-tarsus-pharmaceuticals-enters-retina-market-with-irenix-deal-adds-irx-101-to-pipeline/", "source_name": "TradingView", "published_at": "2026-07-11T14:11:24", "published_display": "11 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing", "summary": "This article analyzes Tarsus Pharmaceuticals Inc. (TARS) using AI models to provide trading strategies. It highlights strong sentiment across all horizons for TARS, suggesting an overweight bias with an exceptional risk-reward short setup. The analysis includes position, momentum", "url": "https://news.stocktradersdaily.com/news_release/1/How_Tarsus_Pharmaceuticals_Inc._TARS_Affects_Rotational_Strategy_Timing_071026061602_1783678562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T06:16:00", "published_display": "10 Jul 2026 06:16", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical, gaining control of IRX-101, an investigational ocular antiseptic designed to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The acquisition involved an upfront payment of approximate", "url": "https://www.visionmonday.com/eyecare/article/tarsus-pharmaceuticals-acquires-irenix-medical-developer-of-late-stage-ocular-antiseptic-irx-101", "source_name": "VisionMonday.com", "published_at": "2026-07-10T04:39:49", "published_display": "10 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Acquires iRenix for $75M", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical Inc. for $75 million, adding the late-stage ocular antiseptic candidate IRX-101 to its portfolio. IRX-101 is designed to improve post-procedural pain and corneal toxicity in patients undergoing intravitreal therapy, building on T", "url": "https://www.ocbj.com/healthcare/tarsus-pharmaceuticals-acquires-irenix-for-75m/", "source_name": "Orange County Business Journal", "published_at": "2026-07-09T17:46:30", "published_display": "09 Jul 2026 17:46", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Buys IRenix Medical", "summary": "This article announces that Tarsus Pharmaceuticals has acquired IRenix Medical. The acquisition suggests Tarsus is expanding its portfolio or capabilities, potentially in the medical device or biotechnology space given IRenix Medical's name. Further details would clarify the stra", "url": "https://www.moomoo.com/news/post/72668950/tarsus-pharmaceuticals-buys-irenix-medical?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T10:11:24", "published_display": "09 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy", "summary": "Tarsus Pharmaceuticals (TARS) has received a rating upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This improvement in the company's earnings outlook is expected to favorably impact its stock price, as changes in future earnings potential are s", "url": "https://au.finance.yahoo.com/news/know-tarsus-pharmaceuticals-tars-rating-160003584.html", "source_name": "Market source", "published_at": "2026-07-09T09:41:30", "published_display": "09 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Acquires iRenix Medical for $75M", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for $75 million in upfront payments (cash and stock), plus potential milestone payments up to $490 million, to expand its eye care portfolio with investigational therapy IRX-101. Despite this strategic move and strong financial s", "url": "https://www.gurufocus.com/news/8950206/tarsus-pharmaceuticals-tars-acquires-irenix-medical-for-75m", "source_name": "GuruFocus", "published_at": "2026-07-09T09:41:26", "published_display": "09 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Q3 2024 earnings summary", "summary": "Tarsus Pharmaceuticals reported record Q3 2024 results with $48.1M in XDEMVY net product sales, an 18% sequential increase. The company expanded payer coverage to over 80% of covered lives, increased its sales force, and launched a direct-to-consumer TV campaign. Financial highli", "url": "https://quartr.com/events/tarsus-pharmaceuticals-inc-tars-q3-2024_F9UefQHo", "source_name": "Quartr", "published_at": "2026-07-09T06:46:30", "published_display": "09 Jul 2026 06:46", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) M&A announcement Summary", "summary": "Tarsus Pharmaceuticals announced an M&A deal to expand into the retina segment, aiming to address unmet needs in ocular surface antiseptics with its IRX-101 product. The acquisition involves an upfront payment of $75 million, with potential milestones up to $490 million and tiere", "url": "https://quartr.com/events/tarsus-pharmaceuticals-inc-tars-m-a-announcement_F9Uenvs0", "source_name": "Quartr", "published_at": "2026-07-09T02:41:26", "published_display": "09 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101", "summary": "Tarsus Pharmaceuticals", "url": "https://www.msn.com/en-us/health/other/tarsus-buys-irenix-medical-for-75m-gains-late-stage-eye-care-asset-irx-101/ar-AA27vwlb", "source_name": "MSN", "published_at": "2026-07-08T22:41:26", "published_display": "08 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals acquires iRenix for $75 million upfront", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for an initial $75 million, consisting of cash and stock. The deal includes potential milestone payments up to $490 million for iRenix's investigational ocular antiseptic, IRX-101. This acquisition is significant as IRX-101 showe", "url": "https://www.investing.com/news/company-news/tarsus-pharmaceuticals-acquires-irenix-for-75-million-upfront-93CH-4782304", "source_name": "Investing.com", "published_at": "2026-07-08T22:41:26", "published_display": "08 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Tarsus Advances Eye Care Leadership Strategy With Acquisition of IRenix Medical and Late-Stage Asset IRX-101", "summary": "Tarsus Pharmaceuticals, Inc. has announced the acquisition of IRenix Medical and its late-stage asset IRX-101, a topical ophthalmic lotilaner solution for dry eye disease. This strategic move aims to strengthen Tarsus's leadership in eye care, leveraging their existing expertise ", "url": "https://www.moomoo.com/news/post/72668041/press-release-tarsus-advances-eye-care-leadership-strategy-with-acquisition", "source_name": "Moomoo", "published_at": "2026-07-08T21:46:30", "published_display": "08 Jul 2026 21:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARS Acquires iRenix Medical for $75M in a Strategic Move", "summary": "Tarsus Pharmaceuticals Inc (TARS) is acquiring iRenix Medical for an initial $75 million, split equally between cash and Tarsus common stock, with potential milestone payments up to $490 million. This strategic acquisition aims to enhance Tarsus's ophthalmic therapeutic portfolio", "url": "https://www.gurufocus.com/news/8950177/tars-acquires-irenix-medical-for-75m-in-a-strategic-move", "source_name": "GuruFocus", "published_at": "2026-07-08T21:03:00", "published_display": "08 Jul 2026 21:03", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for an upfront consideration of approximately $75 million, including cash and stock, plus up to $490 million in potential milestone payments. This acquisition adds IRX-101, a late-stage ocular antiseptic, to Tarsus's pipeline, ai", "url": "https://www.stocktitan.net/sec-filings/TARS/8-k-tarsus-pharmaceuticals-inc-reports-material-event-6f79f14a125e.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:00", "published_display": "08 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Acquires iRenix With $37.5M Cash, Stock; Milestones Up to $490M", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for $37.5 million in cash and 607,093 Tarsus common shares. The deal, which closed on July 6, 2026, includes potential payments of up to $490 million in regulatory and commercial milestones and low-to-mid single-digit revenue sha", "url": "https://www.tradingview.com/news/tradingview:69590c2de739f:0-tarsus-pharmaceuticals-acquires-irenix-with-37-5m-cash-stock-milestones-up-to-490m/", "source_name": "TradingView", "published_at": "2026-07-08T20:39:59", "published_display": "08 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical, gaining IRX-101, an investigational ocular antiseptic aimed at reducing pain and corneal toxicity from intravitreal injections. This acquisition reinforces Tarsus's leadership in eye care, building on positive Phase 2b/3 trial d", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324437/0/en/tarsus-advances-eye-care-leadership-strategy-with-acquisition-of-irenix-medical-and-late-stage-asset-irx-101.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T19:41:26", "published_display": "08 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus pays $75M for eye drug candidate with Phase 3 ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNV0NJcjJJM2QzOUNKMFFoQWZVa1VvemQ1REZuajlubnZ6U3BsdkpObERuZ3pTRnhwZjBINlRqWTlzSlh1TnBHMHdMcng3TGZTbG54SDBMN0FtSzVpWGRSUWo0d2hBSE0xeWhCMEgzaXZaQ2tfaWpaanZPMGZFWkxFSE05bEhSeGlnd0xIcDV6bFNBcHhmek5hOUM0WWNScVJITWFIVFlBaGpfTFRPOE10WkFPV1BlOGJoOU9xRmRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tarsus Pharmaceuticals (TARS) Undervalued Following Culper\u2019s Short Report?", "summary": "Following a short report from Culper Research, Tarsus Pharmaceuticals (TARS) saw its stock price drop, but it now trades at a significant discount to analyst targets and intrinsic value estimates. The report alleged illegal Medicare copay practices and overstated 2026 profit proj", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/is-tarsus-pharmaceuticals-tars-undervalued-following-culpers", "source_name": "Simply Wall Street", "published_at": "2026-07-06T23:41:55", "published_display": "06 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100", "summary": "Mizuho Securities has reiterated its Buy rating on Tarsus Pharmaceuticals (TARS.US) and maintained a price target of $100. This continued positive outlook suggests the firm sees strong potential in the company's future performance. Investors will likely be interested in the ratio", "url": "https://www.moomoo.com/news/post/72517713/mizuho-securities-maintains-tarsus-pharmaceuticals-tarsus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-06T21:40:00", "published_display": "06 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tarsus Pharmaceuticals, Inc. \u2013 NASDAQ:TARS", "summary": "The article discusses the price to sales forward metric for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of financial information available for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-TARS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T20:10:59", "published_display": "04 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQLXkwSHlJcUJJX3VXUDFJMHFXSW5oWUIzZHpvQzRzdTNNNlN6Z3NZZkVtMmNMb3ZOUVlZNnFhd0JhRl9vdHQxbUd2SWxBR3Zvc1ZIYU9MbndDdy1xeG41U2VpYldvZ0VTTkw2UGM3OUI5NlNCVlJQQTB4b1RQRTlqcHFvTVRuNDJIbXo0T1NDbjZPNzRsTWp2M2VtUVhqMlFUZ0E?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Copay Allegations and New Director Equity Awards Just Shift Tarsus Pharmaceuticals' (TARS) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVm5na09iLWFrTGRaQ3J3WG1tUzlFRXZzZW9YWEp5cDNNWVhkVGRsSVgtNEc2WEoxaFF5WFpXWHRHZDVVQnEtSFVETlJSeThWRHJwejFZd1dDeW8yUFl1Y1NoeVdadzE5b1M0Nm85MGdMenJ4aEdlcEdsNjdoYkZOR2dDdjdYQkxvY1daazVxSTM4VXJ5aFBybXdGdm92aHdxVERhNHFfVUxEU3E5ckIyeVBDNzR3UDlsNVcyMw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPQjFsdC0yODEyN295SVNIM0JNUXJUXzZqblc2WW9rZF96YWhqRXJYVEJhSVpudUZISld1WUZVX1lFdmRkWEdHZWRQaWJXNzVoMVBXZlkwdC1BZFUyNmVvdEZJdDJGNkk3eV9HZ3VWbUdjTm4yMjd0TkdySnN4M2FvUU5QWmdTMFBxclEtc3YxdXF3NzFNN3RWczRaa19WWWdrQ0lZQjdnRkJjbzRXUWVqN1JhRTFBOVMxc2M2Rg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TARS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPUmxtRlBockRZT1lWREt1bmdWZDJ0eTNJUlpuSElubm9nVk81R0RMMlFMU1JNQWNXaEVKVG40OFNpNjZJOVh6WUlPc1ladEpLc2laMUNYWERuTm1NZHZqWFhwZTM5akVMbFBEZGNrZU1fTWJoQ2VKc3Z2VUVadXBvU1Y1V0czZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T16:10:33+00:00", "published_display": "25 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNZ0lERzlvM0xYby1wR0x1MHhGeTlVZ2diUEJCcnpPbmFkMHBOV0gtY2ktX3MzOTNySmc1eVBfQ1dMR2QyekQtYTFta3ZBeHBZNUJMY3I0WXNXN2tjLW82SDZjUU1wN0xBZU9tRE9CeGhXdkw0Q01Wci13Zk5tekZFa1kydXpnT1BLWFhJZU1RRGczU0lwTVFxRw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus (TARS) director William Link sells 12,500 shares in planned 10b5-1 trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOMnZRUWF5RVViN0l2djRQYmxUR1c4dXN4SzVaWDlua1N1LU9vTlk2S3J6NE9sdkdsTlhMaDlmbkNDeHhhdHhnb1hhck93NkdCdkdRM0hqaGp5QktYZEsybl9veWpZVzJFWHRCbzVZTWl1bXQ4cGpSbGZid21LajVORi03NHBBY3Y5VklmX2djX0N5Y2FXbEdFZkcxOXlnZ1p3aHlFNlFVWmJnNno0NDJCMEhWYzZpMlFyTlY3Qw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSi1OZURIZjUzXzM4WDBMc1Iza1RWdlRsbzViVXFFM1RQa19LQ2RBSm1UV1FDbFVHbmxSQ1VuSC1HNnlJTGRhUDA0amJzVmplcWFGdFAwN1hHUUJtaXlTS3lxNjQzNHd2YnFrTk9MOWlieTRQZW1jSUFMeDMwMk1tellzNmFCMHVNS2FYOHozS1Bndm12SXZMdnBIY2xfbnZqa2tTVDQyMFNfaEk?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQdERWeWdhUnJBVXRDTkdBeWd3Nm0zMndHU2dORVczV3Atd0Z1bWhBWVBLbzVyLVN0LWIzdm9TSHdNSjN4T2tTMXE1WFZBbWt0LVk2THdIU04zQ3cyRzU2REV3T1h1ZjZ3eDcydGdwYjQ5OGtuMWRFYUh2RTBvazBxaTcyM2NjRFlRYlRNT2RTelhtRVBEbFgzd1VCdGszLXZCOWh0UVlQamV5LW9MUHJXYTh3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUHRwMEl4NEdjYTBkMHp5UHNnWUdBTkxTVVFFRUdwdFktQ0tWeXlDZEdnTEFUMmRKcEpWOVRIQ3VrOHR1X3NxUjR0WUtOUEI4QS1ocC03R2ZQV3Fyd21wN2F4S0FZM3Q1YVFkRkpZTk52RzVzUnJ2YzJBeXlXOEhnYlYwMTZBYWxvRkVIWFhCMmtkN0h3UXBZR05TaUNISlpBdWoxRER3QzM1Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus posts $145M from eye-drop launch, Lyme pill trial starts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNGdJd0oxRGV0aVp3YXR2SGNyTXJMc3g5VDN5bTF1cEFUek5hVDh2SHN4eTJNQTUxWU81bjlMWDlZSXlqQTJiVzZCQ3ZWTjlmYkNmX3hNNDJEd0t5MWhzckxCb1dwYnZES1RvS1ZxcHd1Q3Y3bXp4ZVdLZDJUa1ZoNWRRbUg1U3lPT2diUXJwYnhtQ3VGRl9iem1JZTlCY1pYQWxTaHNXOUNVeUVTUUNEenltUUpMS0Ni?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOcnQ5eTBIQW0tb2VmUGNiT2R0ckpNSXVSeGJQaWhaVWhxSFptRENPOWktUjVfMUUtenlRZWpwbWM0QzRGSGM4NEtlNXJkU3ZUa3JCekVITjFlbjdnVkZ0dWRvWFRGcUREcTV2WjRZY0FKNm1Ed1UzSFItWmJEOEFmXzRFM3BzQ2FvUmVWTGlaWWowUWFsQ1Nfd0RkeVN1TFlMM2ZfdkxVeEtrUkdD?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNcjVsRDVNY2hTTDR6R2w4clVMZkxPUl9SMmZ2cGIxdFl1cUJMaENHMjVzUVI4R1I4Q3RZUHhJdHMyZjltUmsxcTY2bVBzR0YyYkRzZF9uOFFDY0ZHNS13NUxhcnNPMTl2R09HbGJpb1RyRUJTRDF1SkJybTFzYU9TMkpoWk1pU0RIemxNVllVRld6NVV6ZjFDQThKWWpFc3lwWF9Kek01VXNocERPeFpqVnFn?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNZWh1STZueURiWGZZb0Vnd2ZpbmNWVFhfYkkzZWNiZmptRGJvMU5yeGJoWU1MZ3I2NXdiSG14SVFlaHo3UkZ1cm5OMFJhVmF3Z0dKVlpDOWhxQ1RtQW51WFhJVGVqSy1kYlNLWnRLcjVZZzF6WllKdEVlS0syeFotTG1mS2NYZUFKNlBnQ0JnbE9aWWlfXzRSajloeGdXcWZuZnhlZzdtRkg0QWk0cGhjbGFKcjVualdUOWpPamJ0SkI0VXBia0FXcFdHWVM5NFVMM19QSkV0YU9jT2Mz?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPS1lQZjZ1ZF9tNUZrR3gtYjZ3OGtFbE10R09neUU4Q0p2LWx5OFhLQW9VWGc0SEllRUluTDlxX3c4UU1WMmc1M3V6OGdHTXJKeWNoS3B5RkFCSi05V2VhR0o3bE1QalJOU3Q2VWdNdlE3TUtWNERudkN2YnIyck1JeGZ3NUxrRTlaRGlscTVJMUJEekhZUjBsY1gwT29tYXlrTWVidWc4TThxZHl1Tjh3UURQMG83aVc5Vk5DLTV2WE5EeXdSR2hFTFZSbHpxaEItdU9sbGp6cUYycDVmOVhmbDRWT3FpZw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-17T20:01:42+00:00", "published_display": "17 Jul 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/tarsus-pharmaceuticals-tars-replaces-commercial-021119140.html", "source_name": "Simply Wall St.", "published_at": "2026-07-16T02:11:19+00:00", "published_display": "16 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)", "summary": "Analysts have provided new ratings for UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS) in the Healthcare sector. TD Cowen maintained a Hold rating on UnitedHealth with a $430.00 price target, while Mizuho Securities maintained a Buy rating on Tarsus Pharmaceuticals with a $1", "url": "https://www.theglobeandmail.com/investing/markets/stocks/UNH/pressreleases/3290444/analysts-offer-insights-on-healthcare-companies-unitedhealth-unh-and-tarsus-pharmaceuticals-tars/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T11:40:13", "published_display": "15 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Announces Executive Leadership Transition", "summary": "Tarsus Pharmaceuticals has announced a leadership transition where Neera Clase, previously senior vice president of market access, will serve as interim chief commercial officer. This follows the departure of Aziz Mottiwala, who is leaving to become CEO of a public medical device", "url": "https://www.visionmonday.com/eyecare/article/tarsus-pharmaceuticals-announces-executive-leadership-transition/", "source_name": "VisionMonday.com", "published_at": "2026-07-15T04:19:20", "published_display": "15 Jul 2026 04:19", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Chief Commercial Officer Departs", "summary": "Tarsus Pharmaceuticals Inc. announced that its Chief Commercial Officer, Aziz Mottiwala, is departing to become the CEO of an unnamed publicly traded medical device company. Neera Clase, previously SVP of market access, will serve as interim CCO. Following the announcement, share", "url": "https://www.ocbj.com/healthcare/tarsus-chief-commercial-officer-departs/", "source_name": "Orange County Business Journal", "published_at": "2026-07-14T17:11:12", "published_display": "14 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals acquires iRenix for $75 million upfront By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOTlI1eGprT3JJV3ZVc19LMWx1ODR0a3FkajVWMll0ZkZQSl9HMmdPa3YtQ1BmZXNrLUZGSlpwTktSVzZWTkIzUGNreVFKMk5yVTgxWi1wRDdJXy1lRmhVbm13RzZXdy1xMFJVS2FET3JFbHYyaFlnM1dmeUJGNmFqM1pQa0lBSEdZMHRncF9aelUzYkZkc0E4a1UxTzJVUWo2bm9BUURQQlJ5eEdMV29NY0oyanY4Q3JpN2RaNUZhNA?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T15:38:03+00:00", "published_display": "14 Jul 2026 15:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Tarsus commercial executive departs as eye drug XDEMVY gains traction", "summary": "Tarsus Pharmaceuticals announced that Chief Commercial Officer Aziz Mottiwala has left the company to become CEO of a public medical device company. Neera Clase, formerly Senior Vice President of Market Access, has been appointed Interim Chief Commercial Officer. This leadership ", "url": "https://www.stocktitan.net/news/TARS/tarsus-pharmaceuticals-announces-executive-leadership-transition-as-5px5sfcajtke.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:10:21", "published_display": "14 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth", "summary": "Tarsus Pharmaceuticals announced a significant executive leadership transition as the company prepares for its next phase of growth, following the anticipated FDA approval of XDEMVY and its commercial launch. Wendy White is departing from her role as Chief Commercial Officer to p", "url": "https://www.moomoo.com/news/post/72878272/press-release-tarsus-pharmaceuticals-announces-executive-leadership-transition-as-company?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T11:40:13", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/tarsus-pharmaceuticals-appoints-neera-clase-204124445.html", "source_name": "MT Newswires", "published_at": "2026-07-13T20:41:24+00:00", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event", "summary": "Tarsus Pharmaceuticals, Inc. (TARS) announced a material event via an 8-K filing, reporting a leadership change within its commercial organization. Aziz Mottiwala, the Chief Commercial Officer, will depart the company on July 15, 2026, to become the Chief Executive Officer of a p", "url": "https://www.stocktitan.net/sec-filings/TARS/8-k-tarsus-pharmaceuticals-inc-reports-material-event-6d9d590d6719.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:50", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth", "summary": "Tarsus Pharmaceuticals announced an executive leadership transition as Chief Commercial Officer Aziz Mottiwala departs to become CEO of a public medical device company. Neera Clase, previously Senior Vice President of Market Access, has been appointed Interim Chief Commercial Off", "url": "https://ca.finance.yahoo.com/news/tarsus-pharmaceuticals-announces-executive-leadership-200500521.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-13T19:41:50", "published_display": "13 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical, integrating IRX-101, a late-stage ocular surface antiseptic, into its pipeline to expand into the retina market. IRX-101 aims to improve the experience for patients undergoing intravitreal injections by offering a better alterna", "url": "https://www.tradingview.com/news/marketbeat:de5852955094b:0-tarsus-pharmaceuticals-enters-retina-market-with-irenix-deal-adds-irx-101-to-pipeline/", "source_name": "TradingView", "published_at": "2026-07-11T14:11:24", "published_display": "11 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing", "summary": "This article analyzes Tarsus Pharmaceuticals Inc. (TARS) using AI models to provide trading strategies. It highlights strong sentiment across all horizons for TARS, suggesting an overweight bias with an exceptional risk-reward short setup. The analysis includes position, momentum", "url": "https://news.stocktradersdaily.com/news_release/1/How_Tarsus_Pharmaceuticals_Inc._TARS_Affects_Rotational_Strategy_Timing_071026061602_1783678562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T06:16:00", "published_display": "10 Jul 2026 06:16", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical, gaining control of IRX-101, an investigational ocular antiseptic designed to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The acquisition involved an upfront payment of approximate", "url": "https://www.visionmonday.com/eyecare/article/tarsus-pharmaceuticals-acquires-irenix-medical-developer-of-late-stage-ocular-antiseptic-irx-101", "source_name": "VisionMonday.com", "published_at": "2026-07-10T04:39:49", "published_display": "10 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Acquires iRenix for $75M", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical Inc. for $75 million, adding the late-stage ocular antiseptic candidate IRX-101 to its portfolio. IRX-101 is designed to improve post-procedural pain and corneal toxicity in patients undergoing intravitreal therapy, building on T", "url": "https://www.ocbj.com/healthcare/tarsus-pharmaceuticals-acquires-irenix-for-75m/", "source_name": "Orange County Business Journal", "published_at": "2026-07-09T17:46:30", "published_display": "09 Jul 2026 17:46", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Buys IRenix Medical", "summary": "This article announces that Tarsus Pharmaceuticals has acquired IRenix Medical. The acquisition suggests Tarsus is expanding its portfolio or capabilities, potentially in the medical device or biotechnology space given IRenix Medical's name. Further details would clarify the stra", "url": "https://www.moomoo.com/news/post/72668950/tarsus-pharmaceuticals-buys-irenix-medical?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T10:11:24", "published_display": "09 Jul 2026 10:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy", "summary": "Tarsus Pharmaceuticals (TARS) has received a rating upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This improvement in the company's earnings outlook is expected to favorably impact its stock price, as changes in future earnings potential are s", "url": "https://au.finance.yahoo.com/news/know-tarsus-pharmaceuticals-tars-rating-160003584.html", "source_name": "Market source", "published_at": "2026-07-09T09:41:30", "published_display": "09 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Acquires iRenix Medical for $75M", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for $75 million in upfront payments (cash and stock), plus potential milestone payments up to $490 million, to expand its eye care portfolio with investigational therapy IRX-101. Despite this strategic move and strong financial s", "url": "https://www.gurufocus.com/news/8950206/tarsus-pharmaceuticals-tars-acquires-irenix-medical-for-75m", "source_name": "GuruFocus", "published_at": "2026-07-09T09:41:26", "published_display": "09 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Q3 2024 earnings summary", "summary": "Tarsus Pharmaceuticals reported record Q3 2024 results with $48.1M in XDEMVY net product sales, an 18% sequential increase. The company expanded payer coverage to over 80% of covered lives, increased its sales force, and launched a direct-to-consumer TV campaign. Financial highli", "url": "https://quartr.com/events/tarsus-pharmaceuticals-inc-tars-q3-2024_F9UefQHo", "source_name": "Quartr", "published_at": "2026-07-09T06:46:30", "published_display": "09 Jul 2026 06:46", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) M&A announcement Summary", "summary": "Tarsus Pharmaceuticals announced an M&A deal to expand into the retina segment, aiming to address unmet needs in ocular surface antiseptics with its IRX-101 product. The acquisition involves an upfront payment of $75 million, with potential milestones up to $490 million and tiere", "url": "https://quartr.com/events/tarsus-pharmaceuticals-inc-tars-m-a-announcement_F9Uenvs0", "source_name": "Quartr", "published_at": "2026-07-09T02:41:26", "published_display": "09 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101", "summary": "Tarsus Pharmaceuticals", "url": "https://www.msn.com/en-us/health/other/tarsus-buys-irenix-medical-for-75m-gains-late-stage-eye-care-asset-irx-101/ar-AA27vwlb", "source_name": "MSN", "published_at": "2026-07-08T22:41:26", "published_display": "08 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals acquires iRenix for $75 million upfront", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for an initial $75 million, consisting of cash and stock. The deal includes potential milestone payments up to $490 million for iRenix's investigational ocular antiseptic, IRX-101. This acquisition is significant as IRX-101 showe", "url": "https://www.investing.com/news/company-news/tarsus-pharmaceuticals-acquires-irenix-for-75-million-upfront-93CH-4782304", "source_name": "Investing.com", "published_at": "2026-07-08T22:41:26", "published_display": "08 Jul 2026 22:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Tarsus Advances Eye Care Leadership Strategy With Acquisition of IRenix Medical and Late-Stage Asset IRX-101", "summary": "Tarsus Pharmaceuticals, Inc. has announced the acquisition of IRenix Medical and its late-stage asset IRX-101, a topical ophthalmic lotilaner solution for dry eye disease. This strategic move aims to strengthen Tarsus's leadership in eye care, leveraging their existing expertise ", "url": "https://www.moomoo.com/news/post/72668041/press-release-tarsus-advances-eye-care-leadership-strategy-with-acquisition", "source_name": "Moomoo", "published_at": "2026-07-08T21:46:30", "published_display": "08 Jul 2026 21:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TARS Acquires iRenix Medical for $75M in a Strategic Move", "summary": "Tarsus Pharmaceuticals Inc (TARS) is acquiring iRenix Medical for an initial $75 million, split equally between cash and Tarsus common stock, with potential milestone payments up to $490 million. This strategic acquisition aims to enhance Tarsus's ophthalmic therapeutic portfolio", "url": "https://www.gurufocus.com/news/8950177/tars-acquires-irenix-medical-for-75m-in-a-strategic-move", "source_name": "GuruFocus", "published_at": "2026-07-08T21:03:00", "published_display": "08 Jul 2026 21:03", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for an upfront consideration of approximately $75 million, including cash and stock, plus up to $490 million in potential milestone payments. This acquisition adds IRX-101, a late-stage ocular antiseptic, to Tarsus's pipeline, ai", "url": "https://www.stocktitan.net/sec-filings/TARS/8-k-tarsus-pharmaceuticals-inc-reports-material-event-6f79f14a125e.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:00", "published_display": "08 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Acquires iRenix With $37.5M Cash, Stock; Milestones Up to $490M", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical for $37.5 million in cash and 607,093 Tarsus common shares. The deal, which closed on July 6, 2026, includes potential payments of up to $490 million in regulatory and commercial milestones and low-to-mid single-digit revenue sha", "url": "https://www.tradingview.com/news/tradingview:69590c2de739f:0-tarsus-pharmaceuticals-acquires-irenix-with-37-5m-cash-stock-milestones-up-to-490m/", "source_name": "TradingView", "published_at": "2026-07-08T20:39:59", "published_display": "08 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101", "summary": "Tarsus Pharmaceuticals has acquired iRenix Medical, gaining IRX-101, an investigational ocular antiseptic aimed at reducing pain and corneal toxicity from intravitreal injections. This acquisition reinforces Tarsus's leadership in eye care, building on positive Phase 2b/3 trial d", "url": "https://www.globenewswire.com/news-release/2026/07/08/3324437/0/en/tarsus-advances-eye-care-leadership-strategy-with-acquisition-of-irenix-medical-and-late-stage-asset-irx-101.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T19:41:26", "published_display": "08 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus pays $75M for eye drug candidate with Phase 3 ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNV0NJcjJJM2QzOUNKMFFoQWZVa1VvemQ1REZuajlubnZ6U3BsdkpObERuZ3pTRnhwZjBINlRqWTlzSlh1TnBHMHdMcng3TGZTbG54SDBMN0FtSzVpWGRSUWo0d2hBSE0xeWhCMEgzaXZaQ2tfaWpaanZPMGZFWkxFSE05bEhSeGlnd0xIcDV6bFNBcHhmek5hOUM0WWNScVJITWFIVFlBaGpfTFRPOE10WkFPV1BlOGJoOU9xRmRR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Tarsus Pharmaceuticals (TARS) Undervalued Following Culper\u2019s Short Report?", "summary": "Following a short report from Culper Research, Tarsus Pharmaceuticals (TARS) saw its stock price drop, but it now trades at a significant discount to analyst targets and intrinsic value estimates. The report alleged illegal Medicare copay practices and overstated 2026 profit proj", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/is-tarsus-pharmaceuticals-tars-undervalued-following-culpers", "source_name": "Simply Wall Street", "published_at": "2026-07-06T23:41:55", "published_display": "06 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100", "summary": "Mizuho Securities has reiterated its Buy rating on Tarsus Pharmaceuticals (TARS.US) and maintained a price target of $100. This continued positive outlook suggests the firm sees strong potential in the company's future performance. Investors will likely be interested in the ratio", "url": "https://www.moomoo.com/news/post/72517713/mizuho-securities-maintains-tarsus-pharmaceuticals-tarsus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-06T21:40:00", "published_display": "06 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Tarsus Pharmaceuticals, Inc. \u2013 NASDAQ:TARS", "summary": "The article discusses the price to sales forward metric for Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of financial information available for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-TARS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T20:10:59", "published_display": "04 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQLXkwSHlJcUJJX3VXUDFJMHFXSW5oWUIzZHpvQzRzdTNNNlN6Z3NZZkVtMmNMb3ZOUVlZNnFhd0JhRl9vdHQxbUd2SWxBR3Zvc1ZIYU9MbndDdy1xeG41U2VpYldvZ0VTTkw2UGM3OUI5NlNCVlJQQTB4b1RQRTlqcHFvTVRuNDJIbXo0T1NDbjZPNzRsTWp2M2VtUVhqMlFUZ0E?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Copay Allegations and New Director Equity Awards Just Shift Tarsus Pharmaceuticals' (TARS) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVm5na09iLWFrTGRaQ3J3WG1tUzlFRXZzZW9YWEp5cDNNWVhkVGRsSVgtNEc2WEoxaFF5WFpXWHRHZDVVQnEtSFVETlJSeThWRHJwejFZd1dDeW8yUFl1Y1NoeVdadzE5b1M0Nm85MGdMenJ4aEdlcEdsNjdoYkZOR2dDdjdYQkxvY1daazVxSTM4VXJ5aFBybXdGdm92aHdxVERhNHFfVUxEU3E5ckIyeVBDNzR3UDlsNVcyMw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPQjFsdC0yODEyN295SVNIM0JNUXJUXzZqblc2WW9rZF96YWhqRXJYVEJhSVpudUZISld1WUZVX1lFdmRkWEdHZWRQaWJXNzVoMVBXZlkwdC1BZFUyNmVvdEZJdDJGNkk3eV9HZ3VWbUdjTm4yMjd0TkdySnN4M2FvUU5QWmdTMFBxclEtc3YxdXF3NzFNN3RWczRaa19WWWdrQ0lZQjdnRkJjbzRXUWVqN1JhRTFBOVMxc2M2Rg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TARS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPUmxtRlBockRZT1lWREt1bmdWZDJ0eTNJUlpuSElubm9nVk81R0RMMlFMU1JNQWNXaEVKVG40OFNpNjZJOVh6WUlPc1ladEpLc2laMUNYWERuTm1NZHZqWFhwZTM5akVMbFBEZGNrZU1fTWJoQ2VKc3Z2VUVadXBvU1Y1V0czZw?oc=5", "source_name": "TradingView", "published_at": "2026-06-25T16:10:33+00:00", "published_display": "25 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNZ0lERzlvM0xYby1wR0x1MHhGeTlVZ2diUEJCcnpPbmFkMHBOV0gtY2ktX3MzOTNySmc1eVBfQ1dMR2QyekQtYTFta3ZBeHBZNUJMY3I0WXNXN2tjLW82SDZjUU1wN0xBZU9tRE9CeGhXdkw0Q01Wci13Zk5tekZFa1kydXpnT1BLWFhJZU1RRGczU0lwTVFxRw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus (TARS) director William Link sells 12,500 shares in planned 10b5-1 trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOMnZRUWF5RVViN0l2djRQYmxUR1c4dXN4SzVaWDlua1N1LU9vTlk2S3J6NE9sdkdsTlhMaDlmbkNDeHhhdHhnb1hhck93NkdCdkdRM0hqaGp5QktYZEsybl9veWpZVzJFWHRCbzVZTWl1bXQ4cGpSbGZid21LajVORi03NHBBY3Y5VklmX2djX0N5Y2FXbEdFZkcxOXlnZ1p3aHlFNlFVWmJnNno0NDJCMEhWYzZpMlFyTlY3Qw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived Discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSi1OZURIZjUzXzM4WDBMc1Iza1RWdlRsbzViVXFFM1RQa19LQ2RBSm1UV1FDbFVHbmxSQ1VuSC1HNnlJTGRhUDA0amJzVmplcWFGdFAwN1hHUUJtaXlTS3lxNjQzNHd2YnFrTk9MOWlieTRQZW1jSUFMeDMwMk1tellzNmFCMHVNS2FYOHozS1Bndm12SXZMdnBIY2xfbnZqa2tTVDQyMFNfaEk?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQdERWeWdhUnJBVXRDTkdBeWd3Nm0zMndHU2dORVczV3Atd0Z1bWhBWVBLbzVyLVN0LWIzdm9TSHdNSjN4T2tTMXE1WFZBbWt0LVk2THdIU04zQ3cyRzU2REV3T1h1ZjZ3eDcydGdwYjQ5OGtuMWRFYUh2RTBvazBxaTcyM2NjRFlRYlRNT2RTelhtRVBEbFgzd1VCdGszLXZCOWh0UVlQamV5LW9MUHJXYTh3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPUHRwMEl4NEdjYTBkMHp5UHNnWUdBTkxTVVFFRUdwdFktQ0tWeXlDZEdnTEFUMmRKcEpWOVRIQ3VrOHR1X3NxUjR0WUtOUEI4QS1ocC03R2ZQV3Fyd21wN2F4S0FZM3Q1YVFkRkpZTk52RzVzUnJ2YzJBeXlXOEhnYlYwMTZBYWxvRkVIWFhCMmtkN0h3UXBZR05TaUNISlpBdWoxRER3QzM1Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals (TARS) Losses Narrow In Q1 2026 Challenging Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus posts $145M from eye-drop launch, Lyme pill trial starts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNGdJd0oxRGV0aVp3YXR2SGNyTXJMc3g5VDN5bTF1cEFUek5hVDh2SHN4eTJNQTUxWU81bjlMWDlZSXlqQTJiVzZCQ3ZWTjlmYkNmX3hNNDJEd0t5MWhzckxCb1dwYnZES1RvS1ZxcHd1Q3Y3bXp4ZVdLZDJUa1ZoNWRRbUg1U3lPT2diUXJwYnhtQ3VGRl9iem1JZTlCY1pYQWxTaHNXOUNVeUVTUUNEenltUUpMS0Ni?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOcnQ5eTBIQW0tb2VmUGNiT2R0ckpNSXVSeGJQaWhaVWhxSFptRENPOWktUjVfMUUtenlRZWpwbWM0QzRGSGM4NEtlNXJkU3ZUa3JCekVITjFlbjdnVkZ0dWRvWFRGcUREcTV2WjRZY0FKNm1Ed1UzSFItWmJEOEFmXzRFM3BzQ2FvUmVWTGlaWWowUWFsQ1Nfd0RkeVN1TFlMM2ZfdkxVeEtrUkdD?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNcjVsRDVNY2hTTDR6R2w4clVMZkxPUl9SMmZ2cGIxdFl1cUJMaENHMjVzUVI4R1I4Q3RZUHhJdHMyZjltUmsxcTY2bVBzR0YyYkRzZF9uOFFDY0ZHNS13NUxhcnNPMTl2R09HbGJpb1RyRUJTRDF1SkJybTFzYU9TMkpoWk1pU0RIemxNVllVRld6NVV6ZjFDQThKWWpFc3lwWF9Kek01VXNocERPeFpqVnFn?oc=5", "source_name": "Market source", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNZWh1STZueURiWGZZb0Vnd2ZpbmNWVFhfYkkzZWNiZmptRGJvMU5yeGJoWU1MZ3I2NXdiSG14SVFlaHo3UkZ1cm5OMFJhVmF3Z0dKVlpDOWhxQ1RtQW51WFhJVGVqSy1kYlNLWnRLcjVZZzF6WllKdEVlS0syeFotTG1mS2NYZUFKNlBnQ0JnbE9aWWlfXzRSajloeGdXcWZuZnhlZzdtRkg0QWk0cGhjbGFKcjVualdUOWpPamJ0SkI0VXBia0FXcFdHWVM5NFVMM19QSkV0YU9jT2Mz?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 55, "sentiment_summary": {"positive": 22, "negative": 8, "neutral": 25, "score": 59, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}], "positive_events": 22, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 59.85, "latest_week": "2026-07-17", "one_week_move": 2.9, "four_week_move": -5.2, "twelve_week_move": -2.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.198391, "market_dynamics_buy_signal": false, "relative_strength": -17.943831, "fair_value_gap": 34.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.0316, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.9% over one week, -5.2% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "VisionMonday.com", "count": 2}, {"label": "Orange County Business Journal", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 9}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+2.9% over one week, -5.2% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme"}], "updated_at": "2026-07-21T02:53:29.305834+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}